In this Issue
atai Sells a Third of Compass Stake to Raise Cash for In-House Programs
Lykos’ Unproven Psychotherapy Hampered Studies, Claim Authors of New Viewpoint
Picking Placebos for Psychedelic Studies
Small Study of Psilocybin in Severe TRD Among Veterans Shows Promise, But Authors Encourage Tempering Expectations
More Headlines
***
atai Sells a Third of Compass Stake to Raise Cash for In-House Programs
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
